BACKGROUND
The prognostic significance of PD-L1 expression in unresectable/recurrent gastric cancer treated by first-line chemotherapy without an immune checkpoint inhibitor (ICI) remains unclear. The phase III trial JCOG1013 demonstrated no overall survival (OS) or progression-free survival (PFS) benefit of docetaxel/...
H. Hirano, Yasuhide Yamada, Kengo Nagashima et al.· British Journal of Cancer· 0 citations
ABSTRACT Background Long‐term overall survival (OS) of gastric cancer stratified by the prospectively determined clinical stage remains unclear. Methods This is an ancillary study of JCOG1302A, a prospective observational study that evaluated the accuracy of clinical diagnosis of gastric cancer with cT2/T3/T4, cN0/N1/N...
Tsutomu Hayashi, Ryosuke Kato, Noriko Mitome et al.· Annals of Gastroenterologica...· 0 citations
Importance
In the era of modern systemic chemotherapy, the optimal treatment strategy for gastric cancer with positive peritoneal lavage cytology (CY1) and/or localized peritoneal metastasis (P1a) remains controversial.
Objective
To explore the optimal treatment strategy for patients with gastric cancer with CY1 and/...
BACKGROUND
There is currently no established chemotherapy regimen for early recurrence of pathological stage III gastric cancer (GC) following adjuvant chemotherapy with docetaxel plus S-1 (DS) after D2 gastrectomy. We aimed to evaluate the efficacy and safety of ramucirumab plus irinotecan in patients with GC who expe...
Toshifumi Yamaguchi, R. Kawabata, Y. Akamaru et al.· Gastric Cancer· 0 citations
ABSTRACT INTRODUCTION Gastrointestinal stromal tumors (GISTs) are diagnosed based on morphological and immunohistochemical findings. However, in rare instances, GISTs may undergo morphological and immunophenotypic dedifferentiation, making diagnosis challenging. Here, we report a rare case of a rapidly growing gastric...
Kenji Iijima, Tsuyoshi Takahashi, Y. Kurokawa et al.· Surgery Case Reports· 0 citations
Postoperative intervention with ONS did not seem to improve the prognosis of patients receiving adjuvant S-1 treatment, and the number of S-1 courses was a prognostic factor.
Y. Yanagimoto, T. Tsujinaka, Junji Kawada et al.· Anticancer Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.